Beyond Steroids: Biologics and Advanced Therapies for Severe Eczema

Recent Trends in Eczema Treatment

Severe atopic dermatitis management has shifted markedly in the past several years. Dermatologists increasingly prescribe systemic therapies beyond topical corticosteroids for patients who do not achieve adequate control with first-line agents. A growing number of biologic drugs—monoclonal antibodies targeting specific immune pathways—have gained regulatory approvals for moderate-to-severe eczema. Alongside these, oral small-molecule JAK inhibitors have entered clinical use, offering an alternative pill-based option. Treatment guidelines now position these advanced therapies earlier in the treatment algorithm for appropriate candidates, reflecting a broader trend toward precision-driven care.

Background: Limitations of Long-Term Steroid Use

Topical corticosteroids remain a mainstay of eczema management, but their long-term utility is constrained by well-documented drawbacks. Prolonged or high-potency application can lead to skin atrophy, striae, and telangiectasias. A subset of patients experiences topical steroid withdrawal (TSW) upon discontinuation, characterized by intense redness, burning, and rebound flares. Additionally, many individuals with severe disease find that steroids lose effectiveness over time, a phenomenon known as tachyphylaxis. These limitations drove the search for therapies that intervene more directly in the underlying inflammatory cascade.

User Concerns with Advanced Therapies

• Cost and insurance access: Biologics and JAK inhibitors carry significant price tags, often requiring prior authorization or step therapy. Patients may face high out-of-pocket costs even with coverage.
• Injection burden: Most biologic treatments require self-injected or clinic-administered doses every two to four weeks, which can be a barrier for needle-averse individuals or those with logistical constraints.
• Long-term safety data: While short-to-medium-term safety profiles are established, real-world data on risks such as infections, malignancies, or cardiovascular effects continue to accumulate. Patients and clinicians weigh these unknowns against disease severity.
• Non-response or loss of efficacy: A proportion of patients do not achieve clear or almost clear skin, and some who initially respond later lose benefit, requiring therapy switching or dose adjustment.

Likely Impact on Patient Outcomes

For suitable candidates, advanced therapies can substantially reduce eczema burden. Many patients report a dramatic decrease in itch intensity and visible rash within weeks to months, along with fewer disease flares and improved sleep quality. Quality-of-life measures often show meaningful gains. However, these treatments do not cure eczema; they require ongoing administration. The selection of which therapy to initiate depends on patient comorbidities, prior treatment history, and shared decision-making about route of administration and risk tolerance. Access barriers mean that not all severe patients currently benefit equally.

What to Watch Next

Several areas are under active investigation. Newer biologics targeting alternative pathways, such as IL-31 or OX40, are in late-stage trials. Oral JAK inhibitors with potentially improved safety profiles and once-daily dosing continue to undergo post-market evaluation. Research into biomarkers—such as eosinophil counts or serum IgE levels—may eventually help predict which therapy will work best for a given patient. Combination approaches, pairing biologics with lower-potency steroids or topical calcineurin inhibitors, are also being studied. Additionally, biosimilar versions of existing biologics may enter the market, potentially expanding access and lowering costs. Clinicians and patients alike should monitor regulatory updates and evolving real-world evidence to guide treatment decisions.